Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia

Haematologica

Volumn 89, Issue 10, 2004, Pages 1266-1267

  George, Biju ^a   Mathews, Likram ^a   Balasubramanian, Poonkuzhali ^a   Shaji, Ramachandran V ^a   Srivastava, Alok ^a   Chandy, Mammen ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

APML; As2O3; Molecular remission

Indexed keywords

ARSENIC TRIOXIDE; HYDROXYUREA; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG COST; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER TOXICITY; MALE; MOLECULAR BIOLOGY; MOLECULAR REMISSION; NEUTROPENIA; PATIENT MONITORING; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; CHILD; DRUG EVALUATION; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 6344262437     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002;70:292-9.
2. Lu DP, Oiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot trial. Blood 2002;99:3136-43.
3. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis effusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
4. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-9.
5. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Eng J Med 1997;337:120-8.
6. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. P Natl Acad Sci USA 2004;101:5328-35.
7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
8. 3) in the treatment of acute promyelocytic leukemia(APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
9. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, et al. Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997;90:1656-63.
10. Gonzalez M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstein R, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukemia patients according to the PML-RARα isoforms: a study of the PETHEMA group. Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group. Br J Haematol 2001;114:99-103.